Insys Therapeutics Profit Margin 2006-2018 | INSY
Current and historical gross margin, operating margin and net profit margin for Insys Therapeutics (INSY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Insys Therapeutics net profit margin as of September 30, 2018 is -128.88%.
|Insys Therapeutics Annual Profit Margins
|Insys Therapeutics Quarterly Profit Margins
||Medical Products Manufacturing
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.